MarketWatchGE stock surges after $21 billion deal with Danaher, but not enough to clear key chart levelFeb 26, 2019Tomi KilgoreBy Tomi Kilgoremore_vert
The Wall Street JournalGE to Sell Its Biotech Business to Danaher for $21 BillionFeb 25, 2019Thomas GrytaBy Thomas Grytamore_vert
CNBCGE shares surge after Danaher agrees to buy biopharma business for $21.4 billionFeb 25, 2019Michael SheetzBy Michael Sheetzmore_vert